Compare SYNX & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SYNX | BCAB |
|---|---|---|
| Founded | 2005 | 2007 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.9M |
| IPO Year | 2023 | 2020 |
| Metric | SYNX | BCAB |
|---|---|---|
| Price | $0.98 | $3.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.8K | ★ 47.7K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $32.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.73 | $0.12 |
| 52 Week High | $2.15 | $6.52 |
| Indicator | SYNX | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 39.61 | 47.22 |
| Support Level | $0.92 | $3.26 |
| Resistance Level | $1.10 | $3.71 |
| Average True Range (ATR) | 0.04 | 0.31 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.57 | 56.77 |
Silynxcom Ltd is engaged in developing, manufacturing, marketing, and selling ruggedized Personal Headset Devices as well as other communications accessories, all of which have been battlefield-tested and combat proved. It specializes in developing the In-Ear Headset device, a subsegment of the Personal Headset Device market. The In-Ear Headset device is used in both training and operations by the military, law enforcement, and disaster recovery industry professionals. It also develops, markets, and sells push-to-talk devices, communication controllers, and communication device cables and connectors. Geographically, it generates the majority of its revenue from Israel.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.